Analysis of endothelial function of patients with large vessel vasculitis and ANCA-associated small vessel vasculitis

Conditions: M31.5
M31.6
M31.3
M31.7
M30.1
Giant cell arteritis with polymyalgia rheumatica
Other giant cell arteritis
Wegener granulomatosis
Microscopic polyangiitis
Polyarteritis with lung involvement [Churg-Strauss]

Registration Number: DRKS00005139

Lead Sponsor: niversitätsklinikum Jena

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 100

Inclusion Criteria

Patients of the department of rheumatology. Age > 18 years. Presentation of large vessel vasculitis (giant cell vasculitis) or ANCA-associated small vessel vasulitis (Wegener's granulomatosis, Churg-Strauss-syndrom, microskopic polyangiitis) independend of disease activity. Existence of a consent form.

Exclusion Criteria

Patients with another chronic-rheumatic disease or another systemic autoimmune disease. glaucoma or increased intraocular preasure. Coronary heart disease, peripherial artery disease, cerebrovascular disease, nephropathy with renal failure 4-5, diabetes mellitus, instable epilepsy, pregnancy/lactation.

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) RVA-measurement at the right eye using flickerlight after application of Tropicamid 1%: Baseline-measurement of the retinal vessels diameters for 50 seconds and measurement for 80 seconds after application of 20 seconds flickerlight. Performance of 3 of this measurement-circles.<br>2) EndoPAT-measurement: 5 minutes baseline-measurement and 5 minutes measurement after occlusion of the A. brachialis for a duration of 5 minutes.<br>3) laser-doppler-measurement: 5 minutes baseline-measurement and 5 minutes measurement after occlusion of the A. brachialis for a duration of 5 minutes.<br>4) ultrasound-measurement of the intima-media-thickness of the far wall of the A. carotis communis.

Secondary Outcome Measures

Name	Time	Method
1) disease activity and course of disease: Birmingham vasculitits activity score (BVAS V3), vascular damage index (VDI), duration of disease, number/duration/severity of acute attacks; 2) serological inflammation markers; p-/c-ANCAs, PR3, MPO (ELISA); S-Kreatinin, eGFR nach CKD-Epi, Proteinuria, blood picture, HbA1c, blood-lipids, ASAT, ALAT, GGT; 3) serum-concentration of biomarkers: E-Selectin, epidermal growth factor, epidermal growth factor-like domain containing protein 7 and basic-fibroblast growth factor; 4) serum-concentration of circulating endothel cells; 5) serum-concentration of thombocytic microparticles